# SPECIALTY GUIDELINE MANAGEMENT

# TRIKAFTA (elexacaftor/tezacaftor/ivacaftor)

### **POLICY**

### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

# **FDA-Approved Indication**

Trikafta is indicated for the treatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least one *F508del* mutation in the cystic fibrosis transmembrane conductance regulator *(CFTR)* gene or a mutation in the *CFTR* gene that is responsive based on *in vitro* data.

If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one *F508del* mutation or a mutation that is responsive based on in vitro data.

All other indications are considered experimental/investigational and not medically necessary.

## II. DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review: For initial requests, genetic testing report confirming the presence of the appropriate *CFTR* gene mutation.

# **III. PRESCRIBER SPECIALTIES**

This medication must be prescribed by or in consultation with a pulmonologist.

## IV. CRITERIA FOR INITIAL APPROVAL

## Cystic Fibrosis

Authorization of 12 months may be granted for treatment of cystic fibrosis when all of the following criteria are met:

- A. Genetic testing was conducted to detect a mutation in the CFTR gene.
- B. The member has one of the following mutations in the CFTR gene: A46D, A120T, A234D, A349V, A455E, A554E, A1006E, A1067T, D110E, D110H, D192G, D443Y, D443Y; G576A; R668C, D579G, D614G, D836Y, D924N, D979V, D1152H, D1270N, E56K, E60K, E92K, E116K, E193K, E403D, E474K, E588V, E822K, F191V, F311del, F311L, F508C, F508C; S1251N, F508del, F575Y, F1016S, F1052V, F1074L, F1099L, G27R, G85E, G126D, G178E, G178R, G194R, G194V, G314E, G463V, G480C, G551D, G551S, G576A, G576A; R668C, G622D, G628R, G970D, G1061R, G1069R, G1244E, G1249R, G1349D, H139R, H199Y, H939R, H1054D, H1085P, H1085R, H1375P, I148T, I175V, I336K, I502T, I601F, I618T, I807M, I980K, I1027T, I1139V, I1269N, I1366N, K1060T, L15P, L165S, L206W, L320V, L346P, L453S, L967S, L997F, L1077P, L1324P, L1335P, L1480P, M152V, M265R, M952I, M952T, M1101K, P5L, P67L, P205S,

Trikafta 3374-A SGM P2023a

© 2023 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



3374-A

P574H, Q98R, Q237E, Q237H, Q359R, Q1291R, R31L, R74Q, R74W, R74W;D1270N, R74W;V201M, R74W;V201M;D1270N, R75Q, R117C, R117G, R117H, R117L, R117P, R170H, R258G, R334L, R334Q, R347H, R347L, R347P, R352Q, R352W, R553Q, R668C, R751L, R792G, R933G, R1066H, R1070Q, R1070W, R1162L, R1283M, R1283S, S13F, S341P, S364P, S492F, S549N, S549R, S589N, S737F, S912L, S945L, S977F, S1159F, S1159P, S1251N, S1255P, T338I, T1036N, T1053I, V201M, V232D, V456A, V456F, V562I, V754M, V1153E, V1240G, V1293G, W361R, W1098C, W1282R, Y109N, Y161D, Y161S, Y563N, Y1014C, Y1032C, 3141del9, 546insCTA.

- C. The member is at least 2 years of age.
- D. Trikafta will not be used in combination with other medications containing ivacaftor.

## V. CONTINUATION OF THERAPY


Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in Section IV who are experiencing benefit from therapy as evidenced by disease stability or disease improvement (e.g., improvement in FEV1 from baseline).

### VI. REFERENCES

1. Trikafta [package insert]. Boston, MA: Vertex Pharmaceuticals Inc; April 2023.



pharmaceutical manufacturers that are not affiliated with CVS Caremark.





This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of